Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06442436 · ClinicalTrials.gov registry record · Phase 1
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
A Phase 1 study of Hepatic Impairment (HI), sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT06442436: Recruiting Phase 1 study of Hepatic Impairment (HI), sponsored by Merck Sharp & Dohme.
NCT06442436 is a Phase 1 study of Hepatic Impairment (HI) that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06442436, a Phase 1 study of Hepatic Impairment (HI), is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.
Primary Outcome
The AUC0-inf of nemtabrutinib in plasma will be determined in each arm.
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (3)
Florida
- Clinical Pharmacology of Miami ( Site 0003) - Miami
- Orlando Clinical Research Center ( Site 0001) - Orlando
Texas
- Texas Liver Institute ( Site 0002) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2026-09-14 |
| Phase | Phase 1 |
What NCT06442436 shows while recruiting
NCT06442436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Hepatic Impairment (HI) appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT06442436 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06442436 about?
NCT06442436 is a clinical study titled "A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)". The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabruti...
What is the current status of trial NCT06442436?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-07-24. Estimated completion is 2026-09-14.
What conditions does trial NCT06442436 study?
This clinical trial studies the following conditions: Hepatic Impairment (HI).
What interventions are being tested in trial NCT06442436?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT06442436?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06442436 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment (HI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06442436's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI